Flowinmunocell-Bioexocell Group

Flowinmunocell-Bioexocell Group is a biotechnology company specializing in immuno-oncology and cell-free therapies. The company focuses on the development of dendritic cell-derived vesicles (DC-Vesicles) and phospholipoproteomic complexes (PLPC) for immune reprogramming in cancer. Their research emphasizes the stability and functional potency of these vesicles as an alternative to traditional cell-based therapies. They have developed the Structured Traceability and Immunophenotypic Platform (STIP) to standardize the classification of tumor responses. The group operates internationally with key locations in Spain and Chile.